2-Deoxy-3,5-di-O-(4-chlorobenzoyl)-alpha-D-ribofuranosyl Chloride - CAS 21740-23-8
Catalog: |
BB017123 |
Product Name: |
2-Deoxy-3,5-di-O-(4-chlorobenzoyl)-alpha-D-ribofuranosyl Chloride |
CAS: |
21740-23-8 |
Synonyms: |
1-Chloro-3,5-di-(p-chlorobenzoyl)-2-deoxy-D-ribofuranose; 2-Deoxy-α-D-erythro-pentofuranosyl Chloride 3,5-Bis(4-chlorobenzoate); 1-Chloro-2-deoxy-3,5-O-bis(p-chlorobenzoyl)-α-D-erythro-pentofuranose; 3,5-Bis(4-chlorobenzoyl)-2-deoxy-alpha-D-ribofuranosyl Chloride; NSC 140594; 3,5-Di-O-(p-chlorobenzoyl)-2-deoxy-α-D-ribofuranosyl Chloride |
IUPAC Name: | [(2R,3S,5R)-5-chloro-3-(4-chlorobenzoyl)oxyoxolan-2-yl]methyl 4-chlorobenzoate |
Description: | Intermediate used in the synthesis of nucleotide analogs.Unstable in solution. |
Molecular Weight: | 429.68 |
Molecular Formula: | C19H15Cl3O5 |
Canonical SMILES: | C1C(C(OC1Cl)COC(=O)C2=CC=C(C=C2)Cl)OC(=O)C3=CC=C(C=C3)Cl |
InChI: | InChI=1S/C19H15Cl3O5/c20-13-5-1-11(2-6-13)18(23)25-10-16-15(9-17(22)26-16)27-19(24)12-3-7-14(21)8-4-12/h1-8,15-17H,9-10H2/t15-,16+,17-/m0/s1 |
InChI Key: | QEHCZULNFYDPPL-BBWFWOEESA-N |
Boiling Point: | 530.6±50.0°C (Predicted) |
Melting Point: | 110-118°C (dec.) |
Purity: | ≥90% by HPLC |
Density: | 1.46±0.1 g/cm3 (Predicted) |
Solubility: | Soluble in Chloroform (Slightly), Ethyl Acetate (Slightly) |
Appearance: | White to Off-white Solid |
Storage: | Store at -20°C under inert atmosphere |
LogP: | 4.72960 |
GHS Hazard Statement: | H315 (95.12%): Causes skin irritation [Warning Skin corrosion/irritation] |
Precautionary Statement: | P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
WO-2020016782-A1 | Cyclic dinucleotides as sting agonists | 20180717 |
EP-3823976-A1 | Cyclic dinucleotides as sting agonists | 20180717 |
AU-2018215905-A1 | Idoxuridine and its analogs as neuroprotectans for the treatment of parkinsonism | 20170206 |
EP-3576750-A1 | Idoxuridine and its analogs as neuroprotectans for the treatment of parkinsonism | 20170206 |
US-2019388451-A1 | Idoxuridine and its analogs as neuroprotectans for the treatment of parkinsonism | 20170206 |
Complexity: | 516 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 427.998507 |
Formal Charge: | 0 |
Heavy Atom Count: | 27 |
Hydrogen Bond Acceptor Count: | 5 |
Hydrogen Bond Donor Count: | 0 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 427.998507 |
Rotatable Bond Count: | 7 |
Topological Polar Surface Area: | 61.8 Å2 |
Undefined Atom Stereocenter Count: | 3 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 5.4 |
-
Catalog: BB027119
(-)-Di-p-anisoyl-L-tartaric Acid
Detail
-
Catalog: BB021353
(+)-O,O'-Di-p-toluoyl-D-tartaric Acid
Detail
-
Catalog: BB031901
(-)-Diisopropyl D-Tartrate
Detail
-
Catalog: BB036558
(+)-O,O'-Dibenzoyl-D-tartaric Acid Monohydrate
Detail
-
Catalog: BB033577
(-)-2,3:4,6-Di-O-isopropylidene-2-keto-L-gulonic Acid Monohydrate
Detail
-
Catalog: BB027076
(±)-Diethyl trans-4-cyclohexene-1,2-dicarboxylate
Detail
-
Catalog: BB015442
(±)-8a-Methyl-3,4,8,8a-tetrahydro-1,6(2H,7H)-naphthalenedione
Detail
-
Catalog: BB030404
(-)-Citronellal
Detail
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Carbonyl Compounds
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS